Lipum and the Norwegian diagnostics company Age Labs are collaborating to develop a method for predicting which patients with rheumatoid arthritis will respond best to Lipum's drug candidate, SOL-116. The project has a budget of approximately EUR 1.9 million and is funded at 50 per cent by Eurostars, with support from Vinnova and the Research Council of Norway.
- The positive decision from Eurostars enables us to carry out this project together with Age Labs, with the goal of enabling effective and personalised treatment, says CEO Ola Sandborgh.